首页> Toxicologic pathology> Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations.

Regulatory Forum Review*: Utility of in Vitro Secondary Pharmacology Data to Assess Risk of Drug-induced Valvular Heart Disease in Humans: Regulatory Considerations.

导出原文传递

翻译打印收藏纠错

第一作者： Thomas,Papoian

第一单位： 1 Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

作者： Thomas,Papoian ^[1] ; Gowraganahalli,Jagadeesh ^[1] ; Muriel,Saulnier ^[1] ; Natalie,Simpson ^[2] ; Arippa,Ravindran ^[3] ; Baichun,Yang ^[1] ; Adebayo A,Laniyonu ^[4] ; Imran,Khan ^[3] ; Ana,Szarfman ^[1]

作者单位： 1 Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. ^[1] 2 Division of Hematology Oncology Toxicology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. ^[2] 3 Division of Psychiatry Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. ^[3] 4 Division of Medical Imaging Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. ^[4]

关键词 5-HT2B secondary pharmacology valvular heart disease